Award

Metabolic Control of Tissue-Resident Macrophages in Non-Small Cell Lung Cancer Development

Description: <p>Aging is the leading cause of cancer, more than 90% of cancer patients are &ge;50 years old. The US population aged &ge;65 years is estimated to increase from 53 million in 2018 to 88 million in 2050. As this elderly population increases, the financial burden of age-related health disorders especially cancer will increase, and effective preventive and/or therapeutic approaches are urgently needed.</p><p>Aging is a complex process affecting all organs, with functional decline involving various cell-autonomous mechanisms known as the &ldquo;hallmarks of aging.&rdquo; Inflammation is widely recognized as a key driver of aging. An age-associated low-grade, chronic inflammatory state promotes tissue damage and hence this process is referred to as inflammaging. Evidence indicates that monocytes and macrophages in the bone marrow can propagate senescence to distant tissues, contributing to age-related dysfunction, while depletion of senescence macrophages in aged liver tissues mitigate hepatocellular damage. These findings suggest that myeloid cells play a central role in driving aging-associated functional decline. Most recent studies suggest that aging promotes myelopoiesis while reducing the presence of alveolar macrophages (AMs), both of which are linked to an elevated cancer risk. Targeting myelopoiesis or replenishing tissue-resident macrophages, such as AMs, could potentially reverse age-related organ dysfunction in pathological conditions.</p><p>Metabolism, particularly in immune cells, plays a crucial role in both the aging process and age-related diseases. Emerging evidence suggests that metabolic pathways significantly influence macrophage function. By profiling the metabolic features of myeloid cells in aging tissues, we may identify potential targets to rejuvenate macrophage activity and mitigate age-associated organ dysfunction. My preliminary findings show that aging leads to a decline in resident tissue macrophages, such as alveolar macrophages, along with impaired oxidative phosphorylation. Metabolomic profiling and bulk RNA-seq further reveal reduced serine metabolism in these cells. Based on these observations, I hypothesize that restoring alveolar macrophage metabolism by targeting serine metabolism could rescue their function in aged lungs and help counteract cancer progression. <br>My preliminary data suggest that dietary serine supplementation promotes the accumulation of alveolar macrophages in the lung, with a specific enhancement of embryonically derived AMs. In vivo glucose and serine tracing were conducted to investigate how dietary serine influences alveolar macrophages (AMs). In addition, embryonically derived and bone marrow&ndash;derived AMs were isolated from aged mice and subjected to bulk RNA sequencing to examine the mechanisms underlying serine-induced AM accumulation. Last, I pretreated aged mice with dietary serine, and applied KPA-lung cancer model to explore whether AMs involved in cancer development in aged mice.&nbsp;</p>
Amount: CHF 136,000
Funding type: fellowship
Funder scheme: Postdoc.Mobility
Start date: 2025-07-01
End date: 2027-06-30
Investigator: Zhang, Jing (lead)
Institutions: Icahn School of Medicine at Mount Sinai, The Precision Immunology Institute Icahn School of Medicine at Mount Sinai
Subfield: Immunology
Funded outputs count: 0
Funder award ID: 225670
OpenAlex ID: G5920601650